Imatinib mesylate
Imatinib Mesylate is a generic prescription oral tablet medication that inhibits certain enzymes to treat conditions like chronic myeloid leukemia and gastrointestinal stromal tumors. Available in 100mg and 400mg strengths from Chartwell RX, LLC, it was approved under ANDA208429 and first marketed in 2019. This information was generated using AI and is provided for informational and research purposes only.
Complete Metadata
| @type | dcat:Dataset |
|---|---|
| accessLevel | public |
| accrualPeriodicity | R/P1Y |
| bureauCode |
[
"009:10"
]
|
| contactPoint |
{
"fn": "Division of Drug Information",
"@type": "vcard:Contact",
"hasEmail": "mailto:druginfo@fda.hhs.gov"
}
|
| description | Imatinib Mesylate is a generic prescription oral tablet medication that inhibits certain enzymes to treat conditions like chronic myeloid leukemia and gastrointestinal stromal tumors. Available in 100mg and 400mg strengths from Chartwell RX, LLC, it was approved under ANDA208429 and first marketed in 2019. This information was generated using AI and is provided for informational and research purposes only. |
| distribution |
[
{
"@type": "dcat:Distribution",
"title": "Imatinib mesylate",
"mediaType": "text/html",
"description": "
Access the FDA dataset for Imatinib mesylate — ANDA 212773 submitted by Mylan Institutional LLC
",
"downloadURL": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212773"
}
]
|
| identifier | ANDA212773 |
| issued | 2016-09-16 |
| keyword |
[
"drug",
"health-care",
"medications",
"pharmaceuticals",
"public-health"
]
|
| landingPage | https://www.fda.gov/drugs |
| license | https://open.fda.gov/license |
| modified | 2025-03-17 |
| programCode |
[
"009:002"
]
|
| publisher |
{
"name": "U.S. Food and Drug Administration",
"@type": "org:Organization"
}
|
| theme |
[
"FDA"
]
|
| title | Imatinib mesylate |
